High-risk population of progressive hepatic fibrosis in chronic hepatitis B patients on antiviral therapy

被引：0
作者：
Xiujuan Chang
Yinying Li
Chao Sun
Xiaodong Li
Wenjuan Du
Qinghua Shang
Laicheng Song
Qinghua Long
Qin Li
Huabao Liu
Jing Wang
Zujiang Yu
Jiang Li
Guangming Xiao
Li Li
Liang Chen
Lin Tan
Yongping Chen
Yongping Yang
机构：
[1] Fifth Medical Center of Chinese PLA General Hospital,Department of Hepatology
[2] Chinese PLA Medical School,Department of Research for Clinical Medicine
[3] the Fifth Medical Center of Chinese PLA General Hospital,Discipline and Degree Division
[4] the Graduate School of the PLA General Hospital,Center of Therapeutic Liver Disease
[5] the 88th Hospital of Chinese PLA,Department of Infection and Liver Disease
[6] Traditional Chinese Medicine Hospital of Taihe,Department of Infectious Disease
[7] Yichun People’s Hospital,Department of Infectious Diseases, Southwest Hospital
[8] Fuzhou Infectious Diseases Hospital,Department of Traditional Chinese Medicine, Beijing Youan Hospital
[9] Traditional Chinese Medicine Hospital of Chongqing,Department of Hepatic Diseases
[10] Affiliated Traditional Chinese Medicine Hospital of Southwest Medical University,Department of Liver Disease
[11] the First Affiliated Hospital of Zhengzhou University,Department of Infectious and Liver Diseases, Liver Research Center
[12] Army Military Medical University,undefined
[13] Guangzhou 8th People’s Hospital,undefined
[14] Capital Medical University,undefined
[15] Shanghai Public Health Clinical Center,undefined
[16] Fuyang 2nd People’s Hospital,undefined
[17] the First Affiliated Hospital of Wenzhou Medical University,undefined
来源：
Journal of Gastroenterology | 2023年 / 58卷
关键词：
Hepatocellular carcinoma; Hepatic fibrosis; HBeAg; HBsAg; HBcrAg;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：481 / 493
页数：12
相关论文
共 104 条
  • [1] Péneau C(2022)Hepatitis B virus integrations promote local and distant oncogenic driver alterations in hepatocellular carcinoma Gut 71 616-626
  • [2] Imbeaud S(2013)Long-term therapy for chronic hepatitis B: hepatitis B virus DNA suppression leading to cirrhosis reversal J Gastroenterol Hepatol 28 912-923
  • [3] La Bella T(2022)Synergistic effect of Biejia-Ruangan on fibrosis regression in patients with chronic hepatitis B treated with entecavir: a multicenter, randomized, double-blind, placebo-controlled trial J Infect Dis 225 1091-1099
  • [4] Marcellin P(2022)Histological assessment based on liver biopsy: the value and challenges in NASH drug development Acta Pharmacol Sin 43 1200-1209
  • [5] Asselah T(2020)Liver biopsy reliability in clinical trials: thoughts from a liver pathologist J Hepatol 73 1310-1312
  • [6] Rong G(2018)Impact of controlled attenuation parameter on detecting fibrosis using liver stiffness measurement Aliment Pharmacol Ther 47 989-1000
  • [7] Chen Y(2016)Evaluation of APRI and FIB-4 scoring systems for non-invasive assessment of hepatic fibrosis in chronic hepatitis B patients J Hepatol 64 773-780
  • [8] Yu Z(2013)Hepatitis B surface antigen serum level is associated with fibrosis severity in treatment-naive, e antigen-positive patients J Hepatol 58 1089-1095
  • [9] Tong XF(2012)High hepatitis B surface antigen levels predict insignificant fibrosis in hepatitis B e antigen positive chronic hepatitis B PLoS One 7 48-56
  • [10] Wang QY(2016)HBcrAg predicts hepatocellular carcinoma development: an analysis using time-dependent receiver operating characteristics J Hepatol 65 615-625
12345678910